- Generic name
- Paclitaxel
- Strength
- 30 mg/5 ml
- Dosage form
- Injection
- Manufactured by
- Synovia Pharma PLC.
Paxane 30 mg Injection
About Paxane 30 mg Injection
Paxane 30 mg Injection is a cancer chemotherapy medicine given into a vein. It contains paclitaxel and is used in the treatment of certain cancers, including ovarian and breast cancer, under the care of a cancer specialist.
There are 4 brands of Paclitaxel listed in Bangladesh. The lowest listed price is Aritax 6 mg/ml IV Infusion at ৳ 5330.00 per unit.
What is Paxane 30 mg Injection?
Paxane 30 mg Injection is a hospital chemotherapy medicine. Its active ingredient is paclitaxel, which belongs to a group of medicines that interfere with how cancer cells divide and grow. It is given as an intravenous infusion by healthcare professionals trained in cancer treatment. The injection comes as 30 mg/5 ml, and the doctor decides the dose and course for each patient. Because it is a strong cancer medicine, it is given only under close supervision, with monitoring for reactions and side effects during and after treatment.
Uses of Paxane 30 mg
Paxane 30 mg Injection is used to treat advanced cancer of the ovary, both as first-line therapy and in later treatment, often together with cisplatin. It is also used in the adjuvant treatment of node-positive breast cancer, given in sequence after standard doxorubicin-containing treatment. Your cancer specialist will explain how it fits into your particular treatment plan.
How to use Paxane 30 mg
Paxane 30 mg Injection is given by a healthcare professional as an intravenous infusion in a hospital or clinic. Before the infusion, patients are usually given medicines to help prevent severe allergic reactions. The doctor decides the dose, the infusion time and how many cycles you need. The infusion site is watched closely during administration. Do not attempt to use or handle the injection yourself.
Side effects of Paxane 30 mg
Common side effects include low blood counts, which can raise the risk of infection, anemia or bleeding, hair loss, joint and muscle pain, tingling or numbness in the hands and feet, nausea, vomiting, diarrhea, mouth sores, and reactions such as fever, flushing, chills, breathlessness or hives after the injection. Rare effects include swelling of the feet or ankles, liver problems, low blood pressure and skin darkening in areas previously treated with radiation. Tell your care team about any side effect.
Safety and precautions
Paxane 30 mg Injection must be given only under a doctor experienced in cancer chemotherapy, with supportive equipment available in case of a severe allergic reaction. It is not for use in people with severe allergic reactions to paclitaxel or to macrogolglycerol ricinoleate, in people with very low neutrophil or platelet counts, in those with serious uncontrolled infections in Kaposi's sarcoma, or in people with severe liver impairment. Paclitaxel may harm an unborn baby and is not to be used during breastfeeding. Ask your doctor about pregnancy, breastfeeding and any other health conditions before treatment.
Frequently asked questions
What is Paxane 30 mg Injection used for and what kind of medicine is it?
It is a chemotherapy medicine containing paclitaxel. It is used for advanced ovarian cancer, alone or with cisplatin, and for adjuvant treatment of node-positive breast cancer after standard doxorubicin-containing therapy. It is given into a vein by a cancer specialist.
Is Paxane 30 mg Injection safe during pregnancy or breastfeeding?
Paclitaxel may harm an unborn baby, and it is not to be used during breastfeeding. If you are pregnant, think you may be pregnant, or are planning a pregnancy, tell your doctor before treatment. Your doctor will decide what is suitable for you.
Which medicines may interact with Paxane 30 mg Injection?
When paclitaxel is given after cisplatin, blood counts may drop more and clearance of paclitaxel may decrease. Giving paclitaxel close in time to doxorubicin can affect how doxorubicin is cleared. Tell your doctor or pharmacist about every medicine you take, including those bought without a prescription.
Who should not receive Paxane 30 mg Injection?
It should not be given to people with severe allergic reactions to paclitaxel or to macrogolglycerol ricinoleate, to those with very low neutrophil or platelet counts, to people with severe liver impairment, or to those with serious uncontrolled infections in Kaposi's sarcoma. Your doctor will check whether it is suitable for you.
Indications
Breast Carcinoma: Paclitaxel is indicated for ... Read moreOvarian Carcinoma: Paclitaxel is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first line therapy, Paclitaxel is indicated in combination with cisplatin.
Breast Carcinoma: Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracline unless clinically contraindicated. Paclitaxel is indicated for the first-line therapy of advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracline therapy is suitable or in combination with trastuzumab in patients who overexpress HER2 at a 2+ or 3+ level as determined by immuno-histochemistry.
Gemcitabine, in combination of Paclitaxel, is indicated in the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Paclitaxel is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab, in patients who have tumors that over-express HER2 and who have not received previous chemotherapy for their metastatic disease.
Non-Small Cell Lung Carcinoma: Paclitaxel, in combination with cisplatin, is indicated for the first line treatment of non-small cell lung cancerin patients who are not candidates for potential curative surgery and/or radiation therapy.
Kaposi's Sarcoma: Paclitaxel is indicated for the second line treatment of AIDS related Kaposi's Sarcoma.
Gastric Carcinoma: Paclitaxel is indicated for the treatment of Gastric Carcinoma.
Pharmacology
Dosage & Administration
First-line treatment of ovarian cancer: Although alternative medication regimens for paclitaxel are under investigation at present, a combination therapy of paclitaxel and cisplatin is recommended. Depending on the duration of infusion, two different dosages are recommended for paclitaxel treatment: 175 mg/m2 of paclitaxel is administered as an intravenous infusion over a period of three hours followed thereafter by 75 mg/m2 of cisplatin and the therapy is repeated at 3-week intervals, or 135 mg/m2 of paclitaxel is administered as an intravenous infusion over a period of 24 hours followed thereafter by 75 mg/m2 of cisplatin and the therapy is repeated at 3-week intervals.
Second-line treatment of ovarian cancer: The recommended dose of paclitaxel is 175 mg/m2 administered over 3 hours, with a 3-week interval between courses.
Adjuvant chemotherapy in breast carcinoma: The recommended dose of paclitaxel is 175 mg/m2 administered over a period of 3 hours every 3 weeks for four courses, following AC therapy.
First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between courses. When used in combination with trastuzumab, the recommended dose of paclitaxel is 175 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between courses. Paclitaxel infusion may be started the day following the first dose of trastuzumab or immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
Second-line chemotherapy of breast carcinoma: The recommended dose of paclitaxel is 175 mg/m2 administered over a period of 3 hours, with a 3-week interval between courses.
Advanced non-small-cell lung cancer: The recommended dose of paclitaxel is 175 mg/m2 administered over 3 hours followed by 80 mg/m2 of cisplatin, with a 3-week interval between courses.
Treatment of AIDS-related KS: The recommended dose of paclitaxel is 100 mg/m2 administered as a 3-hour intravenous infusion every two weeks.
Dose adjustment: Subsequent doses of paclitaxel should be administered according to individual patient tolerance. Paclitaxel should not be re-administered until the neutrophil count is >1.5 x 109/1 (>1 x 109/1 for KS patients) and the platelet count is >100 x 109/1 (>75 x 109/1 for KS patients).
Interaction
Cisplatin: Administration of paclitaxel after cisplatin treatment leads to greater myelosuppression and about a 20% decrease in paclitaxel clearance. Patients treated with paclitaxel and cisplatin may have an increased risk of renal failure as compared to cisplatin alone in gynecological cancers.
Doxorubicin: Since the elimination of doxorubicin and its active metabolites can be reduced when paclitaxel and doxorubicin are given closer in time, paclitaxel for initial treatment of metastatic breast cancer should be administered 24 hours after doxorubicin. Sequence effects characterized by more profound neutropenic and stomatitis episodes have been observed with combination use of paclitaxel and doxorubicin when paclitaxel was administered before doxorubicin and using longer than recommended infusion times (paclitaxel administered over 24 hours; doxorubicin over 48 hours).
Active substances metabolized in the liver: The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. Therefore, in the absence of a PK drug-drug interaction study, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be compromised because of lower paclitaxel exposures.
Contraindications
- Paclitaxel is contraindicated in patients with severe hypersensitivity reactions to paclitaxel, macrogolglycerol ricinoleate (polyoxyl castor oil.)
- Paclitaxel is contraindicated during lactation.
- Paclitaxel should not be used in patients with baseline neutrophils <1.5x109/I (<1x109/I for KS patients) or platelets <100x109/I (<75x109/I for KS patients).
- In KS, paclitaxel is also contraindicated in patients with concurrent, serious, uncontrolled infections.
- Patients with severe hepatic impairment must not be treated with paclitaxel.
Side Effects
Rare: swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given.
Pregnancy & Lactation
Precautions & Warnings
Significant hypersensitivity reactions, as characterised by dyspnoea and hypotension requiring treatment, angioedema, and generalised urticaria have occurred in <1% of patients receiving paclitaxel after adequate premedication. Fatal hypersensitivity reactions have occurred in patients despite premedication. These reactions are probably histamine-mediated. In the case of severe hypersensitivity reactions, paclitaxel infusion should be discontinued immediately.
Bone marrow suppression, primarily neutropenia, is the dose-limiting toxicity. Neutrophil nadirs occurred at a median of 11 days. Frequent monitoring of blood counts should be instituted. Patients should not be retreated until the neutrophil count is ≥1.5 x 109/1 (≥1 x 109/1 for KS patients) and the platelets recover to ≥100 x 109/1 (≥75 x 109/1 for KS patients).
Severe cardiac conduction abnormalities have been reported rarely with single agent paclitaxel. If patients develop significant conduction abnormalities during paclitaxel administration, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with paclitaxel.
Overdose Effects
Storage Conditions
Alternative brands of Paclitaxel
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.